VOR BIOPHARMA INC

VORNASDAQ

🏆 #2093 by market capEarnings Nov 12US Equity

$22.23▼ $1.29 (−5.79%)

Live

1h▼ 2.2%

24h▼ 5.8%

7d▼ 0.1%

14d▲ 13.6%

30d▲ 23.2%

1y▼ 32.9%

🏦Market Cap

$1.20B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $22.14 – $22.48
52-Week Range: $6.50 – $50.20
Volume: $3.17B
Avg Volume: $2.22B
Shares Outstanding: 54.2M
Next Earnings: Oct 10, 2026

Fundamentals Snapshot

Annual Revenue: $98M
Last Q Revenue: $22M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-293.09
Dividend Yield: —

Why Investors Own VOR

✓High-growth profile — revenue up +41.8% YoY with expanding US Equity exposure.
✓Healthy economics — 40% gross margin and 9% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$98M▲ +42.1% YoY

Gross Margin (TTM)

40.4%▲ +0.9% YoY

Operating Income (TTM)

$30M▲ +42.1% YoY

Free Cash Flow (TTM)

$9M▲ +42.1% YoY

About VOR BIOPHARMA INC

Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.

🦦